NASDAQ OMX

Immunicum AB (publ) Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference

Dela

Press Release

5 February 2018

Immunicum AB (publ) Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference

Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today the presentation of a case study on an individual patient included in the Phase I/II Hepatocellular Carcinoma (HCC) trial at the poster session held during the Cholangiocarcinoma Foundation Annual Conference in Salt Lake City, Utah. The case study highlighted the long survival of one patient with advanced cholangiocarcinoma (bile duct cancer) after combination of the immune primer ilixadencel with standard drugs known to induce immunogenic cell death and inhibit tumor-driven immunosuppression.

"The information from this case study further supports and complements the positive overall safety and immune response data from the Phase I/II HCC clinical study that we announced in September 2017," said Peter Suenaert, Chief Medical Officer at Immunicum. "We value being selected by the Cholangiocarcinoma Foundation to present this one patient's positive response to ilixadencel treatment when combined with certain standard drugs. Presentations at conferences such as this one provide us with a chance to interact with the medical and scientific community focused on treating this rare form of cancer."

In the study, the bile duct cancer patient first received a transarterial chemo-embolization (TACE), which is a standard method to deliver a chemotherapeutic drug directly to the tumor while also restricting blood supply to the tumor. The drug used for this patient was doxorubicin which is known to induce a local immunogenic cell death. The TACE treatment was repeated two times. Ilixadencel, which is aimed to locally recruit and activate endogenous dendritic cells, was administered intratumorally the day after each TACE treatment for a total of three treatments. The tumor did not progress until month 6 at which point the patient received a systemic chemotherapy regimen consisting of gemcitabine + cisplatin, that is believed to lift the immunosuppression in the tumor. The survival of the patient was 41 months, which is positive when compared to historical data. This case study is one example that supports the thesis that treatment with ilixadencel may provide clinical benefit in this form of cancer.

The poster titled, "Combination treatment of immune primer ilixadencel with standard therapy known to inhibit immunosuppression: a case report," was presented at the Cholangiocarcinoma Foundation Annual Conference on February 1, 2018. The poster can be found on Immunicum's website under "Publications" or by accessing the following link: http://immunicum.se/technology/publications/

About Cholangiocarcinoma
Cholangiocarcinoma, or bile duct cancer, arises from the epithelial cells lining the intra- and extrahepatic bile ducts. Intrahepatic cholangiocarcinoma is estimated to account for approximatively 15% of the incidence of primary liver cancers in the US. This tumor type is difficult to diagnose accurately and/or early, so by the time of diagnosis it is often too advanced for surgery, which is currently the only potential curative treatment.

About Cholangiocarcinoma Foundation Annual Conference
The Cholangiocarcinoma Foundation's annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by providing a forum to increase knowledge central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma; presenting a diversity of perspectives focused on clinical, basic, and translational research; stimulating multi-disciplinary, cross-institutional collaborations; and fostering dialogue and inspiring innovation.

About ilixadencel
Ilixadencel, a cell therapy product (formerly known as INTUVAX®), is an off-the-shelf cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells generates an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-cells.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com  

INVESTOR RELATIONS

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com 

Media Relations EU/US

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com 

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Virgin Pulse and RedBrick Health Joining Forces to Create World's Largest Digital Employee Wellbeing and Engagement Company21.5.2018 17:00Pressmeddelande

Merger Will Create First and Only One-Stop-Shop for Employee Health, Wellbeing and Benefits Engagement; Combined Company Will Have More Than 3,300 Customers Across 190 Countries PROVIDENCE, R.I., May 21, 2018 (GLOBE NEWSWIRE) -- Providence-based Virgin Pulse and Minneapolis-based RedBrick Health announced today that the industry pioneers will merge, creating the world's largest, most comprehensive digital health and engagement company. This powerful combination will deliver the industry's only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle - from screening and assessment to activation, behavior change and the adoption of sustainable, healthy habits. "We are thrilled to join with RedBrick to set a new vision and standard for employee health, wellbeing and engagement," said David Osborne, Virgin Pulse CEO, who will serve as CEO of the combined company. "Bringing

Hotels.com App Wins 2018 MediaPost Appy Award in Travel & Tourism Category21.5.2018 16:00Pressmeddelande

Developed by EPAM, app is recognized for creativity and excellence in app design NEWTOWN, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Hotels.com® and EPAM Systems, Inc. (NYSE:EPAM) announced their triumphant win at the 2018 MediaPost Appy Awards in the Travel and Tourism category this week. The Hotels.com mobile app, developed in collaboration with EPAM Systems, Inc., a leading global provider of digital platform engineering and software development services, has been crowned the best app developed for airlines, hotels, travel search engines, destinations, cruises, travel advice or car rentals. With over 70 million downloads and a 4.5+ star rating from consumers on both iOS and Android app stores, the Hotels.com app has now been recognized by the industry leading Appy Awards, which honor creativity and excellence in app design. The app provides a simple, fast and secure way for users to plan, book and manage hotel reservations, and allows travelers to book hundreds of thousands of places to

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Claroty Launches Channel Program and Announces New Industrial Cybersecurity Partnerships21.5.2018 15:00Pressmeddelande

Claroty Vision Program Expands Global Reach and Joint Solution Delivery with OT Leaders, Including Dimension Data/NTT Security, Optiv, and Kudelski Security NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network security, today unveiled Claroty Vision, a new global channel partner program for integrated solution partners, managed service providers (MSPs), and resellers. The program is tailored to provide partners with the tools and resources they need to accelerate revenue in the fast-growing industrial cybersecurity market. The company also announced several new partnerships under the Claroty Vision banner, including the addition of Optiv and Kudelski Security. Comprised of four participation levels - Elite, Premier, Authorized, and Referral - the Claroty Vision program provides partners with a broad range of tools, benefits, and incentives such as increased margin, deal registration, an online demo environment, and co-marketing activitie

Wabtec and GE Transportation to Merge, Creating Global Leader for Rail Equipment, Services and Software21.5.2018 13:00Pressmeddelande

Strategic Combination Will Drive Shareholder Value Creation by Accelerating Innovation in Transportation and Logistics Following the transaction, Wabtec will have approximately $8 billion in revenues, a more diversified business mix, higher margins, and approximately 15 percent cash EPS accretion in year one. Both businesses are expected to benefit from the cyclical tailwinds they are experiencing as industry conditions improve. Complementary businesses and large global installed base will create additional opportunities for cross-selling, aftermarket services growth and new solutions in a rapidly evolving industry. GE Transportation is positioned for a substantial rebound, with estimated adjusted EBITDA growing from about $750 million in 2018 to between $900 million and $1 billion in 2019. Substantial annual run-rate synergies of $250 million and a net present value of approximately $1.1 billion of net tax benefit will accrue to the combined company. The transaction is valued at appro

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum